@article{10.11648/j.ajls.20130101.11,
  author = {Elkhouly EH and Morsi MG and Hamed NA and Soliman AA and Hanafi NF},
  title = {NF. Evaluating Anti β-2 Glycoprotein as Rapid Thromboembolic Marker Among HCV Patients in Egypt},
  journal = {American Journal of Life Sciences},
  volume = {1},
  number = {1},
  pages = {1-5},
  doi = {10.11648/j.ajls.20130101.11},
  url = {https://doi.org/10.11648/j.ajls.20130101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajls.20130101.11},
  abstract = {Although antiphospholipid (APL) antibodies are still not clearly known, yet they have association with thromboembolic events associated with hepatitis C virus (HCV) infection. Moreover, high percent of HCV infections and thromboembolic risk was associated among thalassemic patients. So our aim was to screen and evaluate the significance of ACL and anti β-2 glycoprotein seroprevelance among patients receiving repeated blood transfusions, in patients with infectious diseases as chronic HCV disorders, and in healthy subjects resident in Egypt, a tropical country endemic for hepatitis and to evaluate these tests as rapid markers for early detection of thrombotic HCV infection among chronic liver disorders and cases receiving repeated blood transfusion aiming at early anticoagulant therapy.The study was carried out on 70 patients attending Tropical, Hepatology and Hematology departments in Alexandria Main University Hospital, Egypt as well as 30 healthy subjects served as controls. Group I; 35 chronic liver disorders as chronic HCV, cirrhosis and Hepatocellular carcinoma(HCC) diagnosed by clinical, ultrasound and histopathology. Group II ; 35 receiving repeated blood transfusion as thalassemia. Group III; healthy relatives –ve for HCV antibody of matched age and sex. Both markers were screened by commercial enzyme immunosorbant assays (ELISA) (Calbiotech,USA). Our results revealed that patients with chronic HCV infection had higher anticardiolipin (ACL) IgG and antibeta2GP1 IgG compared to healthy controls. (26.6%) 8 patients from group I had high ACL IgG compared to 6 patients (20%) of group II .The study also revealed that anti β-2 glycoprotein IgG was higher among Group I and II compared to controls group III. Group I was higher than group II. Three patients (10%) of group I had high antiβ2 glycoprotein1 IgG compared to 2 patients (6.6%) among group II . We can conclude that anticardiolipin (ACL)alone is not diagnostic for thrombosis & it should be accompanied with antibeta(β )2glycoprotein-1 in serum of the same patient to be considered a cause of thrombosis in chronic HCV patients. So, ACL alone can not be considered rapid marker of thrombosis in HCV positive patients. We recommend anti β2 glycoprotein as a biomarker predicting thrombotic HCV infection},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - NF. Evaluating Anti β-2 Glycoprotein as Rapid Thromboembolic Marker Among HCV Patients in Egypt
AU  - Elkhouly EH
AU  - Morsi MG
AU  - Hamed NA
AU  - Soliman AA
AU  - Hanafi NF
Y1  - 2013/02/20
PY  - 2013
N1  - https://doi.org/10.11648/j.ajls.20130101.11
DO  - 10.11648/j.ajls.20130101.11
T2  - American Journal of Life Sciences
JF  - American Journal of Life Sciences
JO  - American Journal of Life Sciences
SP  - 1
EP  - 5
PB  - Science Publishing Group
SN  - 2328-5737
UR  - https://doi.org/10.11648/j.ajls.20130101.11
AB  - Although antiphospholipid (APL) antibodies are still not clearly known, yet they have association with thromboembolic events associated with hepatitis C virus (HCV) infection. Moreover, high percent of HCV infections and thromboembolic risk was associated among thalassemic patients. So our aim was to screen and evaluate the significance of ACL and anti β-2 glycoprotein seroprevelance among patients receiving repeated blood transfusions, in patients with infectious diseases as chronic HCV disorders, and in healthy subjects resident in Egypt, a tropical country endemic for hepatitis and to evaluate these tests as rapid markers for early detection of thrombotic HCV infection among chronic liver disorders and cases receiving repeated blood transfusion aiming at early anticoagulant therapy.The study was carried out on 70 patients attending Tropical, Hepatology and Hematology departments in Alexandria Main University Hospital, Egypt as well as 30 healthy subjects served as controls. Group I; 35 chronic liver disorders as chronic HCV, cirrhosis and Hepatocellular carcinoma(HCC) diagnosed by clinical, ultrasound and histopathology. Group II ; 35 receiving repeated blood transfusion as thalassemia. Group III; healthy relatives –ve for HCV antibody of matched age and sex. Both markers were screened by commercial enzyme immunosorbant assays (ELISA) (Calbiotech,USA). Our results revealed that patients with chronic HCV infection had higher anticardiolipin (ACL) IgG and antibeta2GP1 IgG compared to healthy controls. (26.6%) 8 patients from group I had high ACL IgG compared to 6 patients (20%) of group II .The study also revealed that anti β-2 glycoprotein IgG was higher among Group I and II compared to controls group III. Group I was higher than group II. Three patients (10%) of group I had high antiβ2 glycoprotein1 IgG compared to 2 patients (6.6%) among group II . We can conclude that anticardiolipin (ACL)alone is not diagnostic for thrombosis & it should be accompanied with antibeta(β )2glycoprotein-1 in serum of the same patient to be considered a cause of thrombosis in chronic HCV patients. So, ACL alone can not be considered rapid marker of thrombosis in HCV positive patients. We recommend anti β2 glycoprotein as a biomarker predicting thrombotic HCV infection
VL  - 1
IS  - 1
ER  - 

Copy | Download